Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals.
about
Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studiesCause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide studyOptimizing pain management to facilitate Enhanced Recovery After Surgery pathways.The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.Clinical trial data in support of changing guidelines in osteoarthritis treatment.Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications.Cause for concern in the use of non-steroidal anti-inflammatory medications in the community--a population-based studyNonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiativeRelative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.The effect on knee-joint load of instruction in analgesic use compared with neuromuscular exercise in patients with knee osteoarthritis: study protocol for a randomized, single-blind, controlled trial (the EXERPHARMA trial).Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries.Cardiovascular risk of NSAIDs: time to translate knowledge into practiceAll-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study.Activation of α-7 nicotinic acetylcholine receptor reduces ischemic stroke injury through reduction of pro-inflammatory macrophages and oxidative stress.Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.A comparison of self-reported analgesic use and detection of urinary ibuprofen and acetaminophen metabolites by means of metabonomics: the INTERMAP Study.Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice.Indomethacin induced gene regulation in the rat hippocampusHarmful effects of NSAIDs among patients with hypertension and coronary artery diseaseA Comparative Study of the Effect of Prednisolone and Celecoxib on MMO (Maximum Mouth Opening) and Pain Following Removal of Impacted Mandibular Third Molars.Further Effort is Needed to Improve Management of Chronic Pain in Primary Care. Results from the Arkys ProjectEffectiveness of the CardioPain initiative in reducing inappropriate NSAID prescriptions in pain therapy among high cardiovascular risk patients: an informative Italian surveySynthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivativesPANSAID - PAracetamol and NSAID in combination: study protocol for a randomised trial.Anti-cancer small molecule JP-8g exhibits potent in vivo anti-inflammatory activity.Non-steroidal anti-inflammatory drug use and functional outcome from ischemic cerebral events among women.Comparative risks of non-prescription analgesics: a structured topic review and research priorities.Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies.Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC.Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk.Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies.Adverse effects of perioperative paracetamol, NSAIDs, glucocorticoids, gabapentinoids and their combinations: a topical review.Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes.The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective.Cardiovascular disease and non-steroidal anti-inflammatory drug prescribing in the midst of evolving guidelines.Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case-Control Study.High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines.Molecular dynamics investigations of regioselectivity of anionic/aromatic substrates by a family of enzymes: a case study of diclofenac binding in CYP2C isoforms.
P2860
Q21144617-0070BD81-09CB-465D-A625-90852EFD21CCQ28485380-0F94FE95-B755-4789-8A36-1B163697927BQ30369656-48DCD85F-8484-417C-91D7-8DFCF1180E31Q30791071-74302E46-E9A4-408B-A778-D3537A0A0F7AQ30804806-9534CB61-2C05-4526-8E1D-B9769E00EFCAQ33757082-AE344CB1-9CD7-4CC4-8B5C-FCC7742F3039Q33953093-AE98CDA6-46FF-4F13-92E9-1FAB0D5596A8Q34117657-882167E3-DA67-479A-BDAC-EE4005A9DFE9Q34556831-12758ABD-0C49-44D1-857D-1174DB25DF4CQ34558495-0E004FB5-C7DF-47FA-8EEB-B922057D226AQ34592490-A60EBC10-5EA3-4619-96AC-C85E084683E0Q34592497-558D87C3-A235-4150-ACCC-B50F600B86A3Q34996960-E9C9D3E0-1206-4C47-951C-DF331750B686Q35231999-66C83BD2-E3D0-4608-AE05-F994875DC78EQ35251869-3CDD81A1-85E8-4F1A-AA99-C2E54AF63CEEQ35529238-037530AD-AB75-45F9-BFC0-E11C9F3259D1Q35734321-FE7913D2-BAB1-4DF0-9430-EF735B9C284CQ35921866-82027818-C0E5-4F8A-A272-B17B7AC3E8A9Q36126839-C6DF006C-5B0A-4712-ACA9-03A6B141E7DFQ36332332-6D9A8188-5EA9-47B4-80A8-4B14B68C8D30Q36927276-E6D2795A-D429-47DA-B89B-0FDB00A1A684Q37090319-2A61E080-C150-4CCA-9624-A5CFE7B982CBQ37097576-88549A06-976D-4427-82A9-455AE72AB900Q37432633-983EA20F-4260-42FF-B663-DE5B5EAFD592Q37576171-8F90B5A7-E8E0-4304-9EB5-533AFE050854Q37636488-398C6DAC-DE1B-4AB5-89EE-2C204C61E685Q37673214-4C4578DD-E59E-4A67-963F-E73D22938450Q37947341-C6963594-EE25-4CD8-8407-0EFBC5664368Q38101544-00184470-69F0-4C27-90AC-00DD96216757Q38161572-12F5759E-BAEF-4ADD-8A5D-68C704D71692Q38164425-429FA266-34E1-46F1-8601-2D289D48F5CEQ38177340-3075AE1A-F3B8-41AB-9E1E-C6746A810E3DQ38201752-D9F3FB99-8E93-455F-8E15-11A9BA43DA77Q38239354-071FFE16-199E-4154-8634-1C91B5EA72CAQ38249105-20AC00C8-7A6E-47DD-ACC9-0D112E691E98Q38316845-83B4622F-BFD0-4F07-A41B-FEA9DC73A71EQ38429068-950E8F29-1A68-4716-9B03-797535EDE110Q38693695-2EA70563-8965-498E-8C0A-3CD694021B04Q38808074-FFF72810-E2FE-4302-B14D-0794143A5169Q38853146-E0F27BB2-94B8-490B-A98C-06DDBAF655AD
P2860
Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cause-specific cardiovascular ...... ugs among healthy individuals.
@ast
Cause-specific cardiovascular ...... ugs among healthy individuals.
@en
Cause-specific cardiovascular ...... ugs among healthy individuals.
@nl
type
label
Cause-specific cardiovascular ...... ugs among healthy individuals.
@ast
Cause-specific cardiovascular ...... ugs among healthy individuals.
@en
Cause-specific cardiovascular ...... ugs among healthy individuals.
@nl
prefLabel
Cause-specific cardiovascular ...... ugs among healthy individuals.
@ast
Cause-specific cardiovascular ...... ugs among healthy individuals.
@en
Cause-specific cardiovascular ...... ugs among healthy individuals.
@nl
P2093
P50
P1476
Cause-specific cardiovascular ...... ugs among healthy individuals.
@en
P2093
Emil Loldrup Fosbøl
Jeppe N Rasmussen
Rikke Sørensen
Søren Jacobsen
Søren Rasmussen
Søren S Andersen
Tina Ken Schramm
P304
P356
10.1161/CIRCOUTCOMES.109.861104
P577
2010-06-08T00:00:00Z